Fairmount Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-751,804
| Closed | -$12.3M | – | 17 |
|
|
2022
Q3 | $12.3M | Hold |
751,804
| – | – | 2.16% | 16 |
|
|
2022
Q2 | $10.6M | Sell |
751,804
-405,013
| -35% | -$5.71M | 2.42% | 18 |
|
|
2022
Q1 | $28M | Buy |
1,156,817
+740,000
| +178% | +$17.9M | 6.62% | 7 |
|
|
2021
Q4 | $9.73M | Hold |
416,817
| – | – | 3.21% | 11 |
|
|
2021
Q3 | $6.92M | Sell |
416,817
-7,000
| -2% | -$116K | 2.52% | 16 |
|
|
2021
Q2 | $10.3M | Sell |
423,817
-8,500
| -2% | -$207K | 4.25% | 10 |
|
|
2021
Q1 | $11.2M | Sell |
432,317
-18,000
| -4% | -$464K | 4.7% | 11 |
|
|
2020
Q4 | $24.1M | Sell |
450,317
-197,516
| -30% | -$10.6M | 8.61% | 4 |
|
|
2020
Q3 | $26.7M | Buy |
647,833
+62,316
| +11% | +$2.57M | 11.32% | 2 |
|
|
2020
Q2 | $28.4M | Sell |
585,517
-18,000
| -3% | -$872K | 12.66% | 1 |
|
|
2020
Q1 | $25.5M | Buy |
603,517
+87,729
| +17% | +$3.71M | 15.47% | 1 |
|
|
2019
Q4 | $22.1M | Buy |
+515,788
| New | +$22.1M | 13.37% | 3 |
|